Theragen ETEX said Friday that it has signed a memorandum of understanding with Bioneer to conduct research and develop projects related to genome analysis jointly.

Theragen ETEX CEO Hwang Tae-soon (left) and Bioneer CEO Park Han-oh hold up their agreement at Bioneer headquarters in Daejeon, last Thursday.

Under the accord, the two companies will strategically cooperate on technology advancement research and services in the area of next-generation sequencing, while planning to share research capabilities and assets, support the mutual use of facilities and equipment, and exchange information.

Theragen plans to utilize its industry-leading research facilities, personnel, and technology in the field of genome analysis, while Bioneer will use its key technologies in gene technology, including the development of equipment and diagnostic kits.

“This agreement is expected to result in not only R&D achievement but also business developments,” Theragen ETEX CEO Hwang Tae-soon said. “We will do our best to make the most of the advantages of both companies.”

Bioneer CEO Park Han-oh also said, “Theragen ETEX's genomic analysis technology and Bioneer' s automation equipment and related reagent will enable both companies to increase their competitiveness in the domestic genomics analysis and diagnostic testing market.”

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>